Skip to main content
Pay Bill Portals

Medicare Expands Coverage of Signatera for Patients with Lung Cancer

Published Date

Medicare now covers Signatera™, a personalized molecular residual disease (MRD) test, for patients with stage I-III non-small cell lung cancer (NSCLC) in the surveillance setting. This means more people can access a test that helps detect cancer recurrence earlier and understand how well treatment is working.

Why This Matters to You

If you’ve had treatment for lung cancer, ongoing monitoring is important. Traditional follow-up tools like CT scans don’t always catch cancer recurrence early enough or clearly show what’s happening. Signatera is different—it looks for tiny traces of cancer in your blood, often months before a scan would show any changes. It can also help your doctor see if your treatment is working or if adjustments might be needed.

Who Can Get This Test?

Medicare now covers patients with stage I-III NSCLC for testing every six months in the surveillance setting. Medicare also covers any lung cancer patient being treated with immunotherapy. This gives you and your doctor regular updates on your condition.

How Signatera Can Help You

  • Catch Cancer Earlier: Find out if cancer is coming back before symptoms appear.
  • Know If Treatment Is Working: Signatera tracks changes over time, helping you and your doctor make informed choices.
  • Get Clearer Answers: With a high accuracy rate (93-100% sensitivity, 96-100% specificity), this test helps remove uncertainty in follow-up care.

What This Means for You

With this expanded Medicare coverage, more patients with lung cancer can get the benefits of advanced monitoring. Whether you’re keeping an eye on recurrence or checking your treatment’s progress, Signatera offers a more precise way to stay informed about your cancer care.

For more details, read the full announcement here.